ArticleDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy2022
Dual use of antifungals in medicine and agriculture: How do we help prevent resistance developing in human pathogens?
Article in Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Azole resistance inFrontiers in veterinary science · 2025Pooled it
- Modelling the role of the microbiome in antimicrobial resistance across scales.Nature microbiology · 2026Review
- Addressing the dual-use of antifungals and fungal antimicrobial resistance (fAMR) through a One Health approach.npj antimicrobials and resistance · 2026Review
- Thermal adaptation crosstalk with azole response through lncRNA inbioRxiv : the preprint server for biology · 2026Article
- Tetflupyrolimet shows selectivity for plant dihydroorotate dehydrogenase over Aspergillus orthologs.Scientific reports · 2026Article
- Characteristics of individualAntimicrobial agents and chemotherapy · 2026Article
- Novel Genetic Diversity and Geographic Structures ofMicroorganisms · 2026Article
- Antifungal and fungicide susceptibility of clinical, animal, and environmental Fusarium and Neocosmospora species from Colombia: a one-health approach.Scientific reports · 2025Article
- Antifungal treatment strategies and their impact on resistance development in clinical settings.The Journal of antimicrobial chemotherapy · 2025Review
- Article
- One-Health Approach to Managing Aflatoxin-Producing Aspergillus flavus Using Spent Mushroom Substrate ofACS omega · 2025Article
- Article
- Global, Regional, and National Burden of Pulmonary Fungal Infections 1990-2021.American journal of respiratory and critical care medicine · 2025Article
- Urbanisation and Lockdown Impact on Airborne Fungal Communities in Tropical Landscapes: A Comparative Study of Urban and Peri-Urban Environments.Environmental microbiology reports · 2025Article
- The Impact of Epidemiological Trends and Guideline Adherence on Candidemia-Associated Mortality: A 14-Year Study in Northeastern Italy.Journal of fungi (Basel, Switzerland) · 2025Article
- Doubling of triazole resistance rates in invasive aspergillosis over a 10-year period, Belgium, 1 April 2022 to 31 March 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Refractory versus resistant invasive aspergillosis.The Journal of antimicrobial chemotherapy · 2025Review
- Article
- Susceptibility and resistance of Gram-negative bacteria to a novel antimicrobial agent TGV-49.Frontiers in antibiotics · 2025Article
- Elevated mutation rates in multi-azole resistant Aspergillus fumigatus drive rapid evolution of antifungal resistance.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 5 countries.
Funding
Abstract
Azole resistance in Aspergillus fumigatus is a One Health resistance threat, where azole fungicide exposure compromises the efficacy of medical azoles. The use of the recently authorized fungicide ipflufenoquin, which shares its mode-of-action with a new antifungal olorofim, underscores the need for risk assessment for dual use of antifungals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.